TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01562249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orofacial myofunctional treatment protocol
Description: Once a week for six weeks, the experimental group received a forty minutes session of orofacial myofunctional treatment. A home exercise program was prescribed during each session. The protocol implies in continuous and daily practices - participants were asked to perform exercises at least three times a day. After the first six weeks, the experimental group underwent four sessions for maintenance purposes (two sessions twice a month and two sessions once a month). The total treatment duration was of five months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling
Description: The instruction group underwent two supervised forty minutes therapy sessions along the six weeks following surgery. These sessions involved the perception of the stomatognathic system, especially in terms of adequate performance during mastication. Specific exercises were not given and patients were instructed to try to reproduce the adequate pattern of mastication at all meals (i.e. alternated bilateral, with lip closure; with coordination activity of the tongue and mandible).

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control Group
Description: As the sEMG test-retest is a critical issue, participants of CG were also tested in two distinct moments (testing occurred with 1 year interval) in order to verify possible changes in the sEMG measurements as a result of retesting.
Study: NCT00265525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CardioFit
Description: CardioFit is a 26-week tailored web-based physical activity coaching service for individuals with Coronary Artery Disease (CAD). It has been designed to help patients develop personalized exercise programs based on their medical history, personal goals and preferences. Access to Cardio-fit is through a secured website. The cardio-fit website contains physical activity advice and heart health educational information. Each patient is assigned an on-line coach, whose role is to assist in creating safe an effective physical activity program, and to answer any questions that patients may have throughout the program.
Study: NCT04267588

Intervention type: OTHER
Intervention: Navio Mobile App
Description: Participants will use the Navio Mobile App to track participants' pain and pain treatment
Study: NCT01805973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Patients will participate in a supervised exercise training programme for 18 weeks. Patients will participate in a 50 minute exercise regime three times a week.
Study: NCT01034241

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Diet consists of 15 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dairy protein
Description: Diet consists of 25 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vegetable protein
Description: Diet consists of 15 En% vegetable protein and low GI, 55 En% carbohydrates and 30 En% fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High GI
Description: Diet consists of 15 En% dairy protein and high GI, 55 En% carbohydrates and 30 En% fat
Study: NCT02310893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Contingency Management and Peer Navigation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Navigation
Study: NCT04206137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A (PNF rhythmic initiation group )
Description: Lifting of arms and push the head back through the pattern of flexion -abduction-external rotation and neck in extension to the left in opposition of therapist hand resistance will be asked to do. At the end range of motion extensor muscles of back will start to contract.Then, reversing of that movement pattern to extension-adduction-internal rotation and neck flexion to right against the therapist resisting hands will be asked. this will be repeated on both sides

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B (Swiss ball exercises)
Description: Supine position: A ball will be placed under patient neck, and will be asked to bend hip and knee up to 90°. 5 times, 10 seconds hold Supine position: With a ball below the pelvis, knees bent, the ball press will be done with pelvis. 5 times, for 10 seconds hold.~Crawling position: With a ball below one knee while keeping toes away from contact with the floor, the patient will balance first to stabilize the posture and slowly raise the other lower limb. This exercise will be performed in turn for the two lower limbs 10 times, with 10 seconds hold.~Prone position: the patient will place a ball in front of pelvis and will repeatedly raise and lowered the two lower limbs alternately. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set.
Study: NCT04505449

Intervention type: DIAGNOSTIC_TEST
Intervention: Left heart catheterization
Description: Patients who underwent left heart catheterization
Study: NCT01010958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).
Study: NCT01018160

Intervention type: DRUG
Intervention: Rabeprazole Sodium
Description: 10mg - 20mg tablet once or twice daily for 12 weeks
Study: NCT03559439

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR T
Description: CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10\^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.
Study: NCT01448044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052 (NS5A Replication Complex Inhibitor)
Study: NCT03091075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: Treatment group will receive Oxandrolone daily for 12 weeks postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will receive placebo for 12 weeks postoperative
Study: NCT03564795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KeraStat Gel
Description: Wound dressing for partial thickness burns

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silver Sulfadiazine
Description: Wound dressing for partial thickness burns
Study: NCT02470403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 25 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LIK066
Description: LIK066 25 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LIK066
Description: LIK066 25 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT01903681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Circadin 2 mg
Description: First arm lower dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Circadin 10 mg
Description: Second arm higher dose
Study: NCT03802435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two-sessions of ultrasound-guided PIT
Description: two-sessions of ultrasound-guided PIT with 10cc D5W (3 months interval)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-sessions of ultrasound-guided PIT
Description: One-session of ultrasound-guided PIT with 10cc D5W and 10cc normal saline separately (3 months interval)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ultrasound-guided injection with nerve hydrodissection
Description: Two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
Study: NCT01933178

Intervention type: DEVICE
Group type: OTHER
Intervention: Cirrus AS-OCT
Study: NCT04294251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP450
Description: Botulinum toxin type A(DWP450) will be administered intramuscularly to the bilateral masseter muscles on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(Normal Saline) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
Study: NCT03559803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Drug: Cisplatin injection Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.~Combination Product: radiotherapy A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
Study: NCT04093492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemie Prep for Parents (P3) Outpatient Mobile Intervention
Description: The P3 mobile intervention sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACOG links
Description: Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
Study: NCT00257205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Description: decarbazine 1000 mg/m2 IV Q 21 days x 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: CP-675,206 15 mg/kg IV Q 90 days x 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
Study: NCT02278692

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K
Description: Oral vitamin K

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablet
Study: NCT01053130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sleeve gastrectomy
Description: laparoscopic sleeve gastrectomy plus dietary and physical activity support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight management program
Description: 1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months
Study: NCT00087126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study: NCT04764786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVOO+POLY
Description: a test meal seasoned with extra virgin olive oil rich in polyphenols

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OO-POLY
Description: a test meal seasoned with olive oil poor in polyphenols
Study: NCT05260424

Intervention type: OTHER
Intervention: non-invasive ventilation
Description: Babies who will have or won't have non-invasive ventilation failure in the first 72 hoursof life, will be compared.

Intervention type: OTHER
Intervention: non-invasive ventilation
Description: Babies who will have or won't have non-invasive ventilation failure in the first 72 hoursof life, will be compared.
Study: NCT01448044

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-790052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alfa 2a

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated-interferon alfa 2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Study: NCT01799720

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Less oxidized oil and diet
Description: Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, . Follow-up 30 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: More oxidized oil and diet
Description: Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 2 took 2 capsules/day of one of the more oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemic diet
Description: Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
Study: NCT01162941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steroid refractory ITP
Description: a platelet count less than 20X109/L despite of treatment with full dose of steroid (prednisolone 1mg/kg for at least 4 weeks)
Study: NCT02210962

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: essential fatty acids
Description: Yellow capsules containing eicosapentaenoic acid, docosahexaenoic acid (active)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: Yellow capsules containing olive oil (placebo)
Study: NCT02916004

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of NFR and PDR
Description: Feasibility testing of NFR and PDR in sedated, ventilated patients. Comparison of NFR and PDR with standard routine care of pain assessment
Study: NCT02394899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play therapy
Description: Short films that have been developed to deliver a series of child development messages will be shown at the monthly visits. Nine modules of approximate length 3 minutes each have been developed and cover the topics: Love, Comforting baby, Talking to babies and children, Praise, Using bath time to play and learn, Looking at books, Simple toys mothers can make, Drawing and games, and Puzzles. Nurses at the Sickle cell Unit (SCU) will be trained to discuss the video messages with the mothers/caregivers, demonstrate activities they can do with their children and how to make simple toys from household materials. Mothers/caregivers will practice some of the activities and they will be encouraged to make them part of their daily routine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem solving skills
Description: Problem solving therapy (PST) aims to empower patients or caregivers in attending to daily challenges. It is based on cognitive behavioural therapy and can be used in primary care settings. It encourages persons to use existing resources and skills to function better and find solutions to problems. It will be delivered in 6 sessions over the 6-week period and will last for about 30 minutes per session. The stages of PST are: identification of the problems; generating possible solutions; evaluating and implementing preferred solution; and evaluating to see if the solutions were successful. The parent/caregiver will be taught a process of problem solving with reference to general everyday problems as well as specific problems which may arise while parenting a child with SCD.
Study: NCT05015673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP363856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP363856

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02773706

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated Psychology Services
Description: The automated screening tool determines a positive or negative screen, then informs the clinician, and also automates a psychology visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification of Subspecialist
Description: The automated screening tool determines a positive or negative screen, then informs the clinician.
Study: NCT04387539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF/SMV/DCV/RBV
Description: SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF/SMV/DCV/RBV
Description: SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.
Study: NCT01304082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1 ml subcutaneous injection of 0.9% lidocaine, given once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 1 ml subcutaneous injection 0.9% sodium chloride, given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alkalinized lidocaine
Description: 1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
Study: NCT03049657

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiolite
Description: Percutaneous coronary intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience
Description: Percutaneous coronary intervention
Study: NCT00823732

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Undergo individualized interdisciplinary palliative care intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical chart review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: end-of-life treatment/management
Description: Undergo end-of-life treatment/management

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Description: Undergo psychosocial assessment and care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: Undergo management of therapy complications

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: assessment of therapy complications
Description: Undergo assessment of therapy complications
Study: NCT03217734

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneous Injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT01673360

Intervention type: DEVICE
Intervention: Elevate PC
Description: List of AMS prolapse products

Intervention type: DEVICE
Intervention: Mini Arc Pro
Description: List of AMS Urinary Incontinence devices

Intervention type: DEVICE
Intervention: RetroArc
Description: List of AMS Urinary Incontinence devices
Study: NCT01782963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01264029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Tai Chi Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mall Walking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly Discussion
Study: NCT01276249

Intervention type: DEVICE
Intervention: Fortevo Endograft
Description: The Fortevo Endograft, Main Body and Iliac Lumen Delivery System are indicated for the endovascular treatments of patients with infrarenal abdominal aortic aneurysms or aortic-iliac aneurysms having suitable morphology for endovascular repair.
Study: NCT00941278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10 (0.001% Rose Bengal)
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Study: NCT02838628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg of KX2-391 Ointment 1%
Description: Dose: 50 mg; Route of administration: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg of KX2-391 Ointment 1%
Description: Dose: 50 mg; Route of administration: Topical
Study: NCT02397460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant tablets administered orally as a single dose of 50 mg (1 tablet) or 300 mg (6 tablets)
Study: NCT02966119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel or Aspirin and/or Dypyridamole
Description: The physician will prescribe on this antiplatelet agent if the patient is randomized in the arm  restart